News

Committee for Medicinal Products for Human Use Adopts Positive Opinion For Plegridy As a Treatment for MS In The European Union

TheĀ CommitteeĀ for Medicinal Products for Human UseĀ (CHMP) of the European Medicines AgencyĀ recently offered a positive opinion for the marketing authorization of Biogen Idec’s Plegridy therapy, a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS). The positive opinion will now be sent to the European Commission, which grants…

Benefits of Cognitive Reserve in Multiple Sclerosis May Also Benefit TBI Patients

Researchers from theĀ Kessler FoundationĀ have found that higher educational achievement reduces the negative impact ofĀ traumatic brain injuryĀ (TBI) on cognitive status. The study appeared inĀ Archives of Physical Medicine & Rehabilitation. It was reported in the study that cognitiveĀ ability after experiencing TBI differs in individuals even when their injury levelsĀ were comparable. As…